REG - Kromek Group PLC - New Nuclear Security Orders

KromekAnnouncement

28/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250528:nRSb3101Ka&default-theme=true

RNS Number : 3101K  Kromek Group PLC  28 May 2025

28 May 2025

 

Kromek Group plc

("Kromek" or the "Group")

 

New Nuclear Security Orders

Two orders to supply D3 series detectors to a European and a US customer

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments, is pleased to announce that it has received two orders to supply its
D3 series of detectors for use by a European and a US customer.

 

The orders, valued together at approximately $900k, are for immediate
delivery. The European customer is dedicated to fostering civilian science and
technology partnerships aimed at mitigating global CBRN security risks and
advancing non-proliferation efforts. The US customer is a leading supplier of
integrated products working in the defence and security sector with a history
of implementing innovative security solutions.

 

The customers will receive the Group's D3 series of detectors to enhance their
capabilities in the timely detection of radiation levels, as well as to
facilitate data collection and processing and real-time data transmission.
This will enable better informed decision-making and rapid responses to
potential threats to national safety and security.

 

Arnab Basu, Chief Executive Officer of Kromek, said: "We are pleased to
announce the receipt of these new orders that underscore our continued
commitment to providing advanced detection solutions for emergency response
services. Our proprietary technology is instrumental in mitigating
radiological and nuclear threats through rapid, reliable detection and
real-time data transmission capabilities.

 

"In an environment marked by ongoing geopolitical uncertainty, demand for our
solutions continues to grow, highlighting Kromek's vital role in supporting
global safety and security efforts. These orders reflect the increasing trust
in our innovative technologies and further solidify Kromek's position as a
leading provider in the critical security market."

 

For further information, please contact:

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Paul Farquhar, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220  0500

 Tim Redfern - ECM

 Michael Johnson - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury/Henry Gamble                              +44 (0)20 4582 3500

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect critical
infrastructure, events, personnel and urban environments from the threat of
'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFFFVIEVIDFIE